Summary
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
History
Can-Fite BioPharma was established in 2000 as a fully integrated pharmaceutical company focused on the development of novel small molecule therapeutics. In 2011, the company’s drug candidate, CF101, was approved by the Ministry of Health in Israel. The company began trading on the Tel Aviv Stock Exchange in 2012. The company has two other clinical stage drug candidates in its pipeline, CF102 and CF602.
Mission
To provide innovative therapeutics to patients by utilizing novel small molecules that target disease pathways with unmet medical need.
Vision
To become a global leader in the development of novel small molecules for the treatment of chronic inflammatory and cancer diseases.
Key Team
Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D. (Sr. Clinical Advisor)
Dr. Ilan Cohn Ph.D. (Co-Founder & Chairman)
Recognition and Awards
2012– Can-Fite BioPharma is the recipient of the Red Herring Top 100 award for the most innovative North American and European technology companies.
References
Israel 